Slides
Page 1
Q3 Report 2025/26 1 October 2025 – 30 June 2026 This presentation contains statements regarding expectations for the future development of RTX A/S, including future revenue and operating profit (EBITDA), reflect Management’s current outlook and carry some uncertainty. These statements can be affected by a number of risks and uncertainties, which means that actual developments and results can be materially different from the expectations expressed directly or indirectly in this presentation of the interim report. These risks and uncertainties include, but are not limited to, general economic conditions and developments, changes in demand for RTX’s products and services, competition, technological changes, fluctuations in currencies, component availability, and fluctuations in sub-contractor supplies as well as legislative and/or regulatory changes. This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 2
RTX is everywhere RTX - Q3 2025-26 investor presentation We provide secure and reliable communication products and solutions, fit for challenging environments 2 This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 3
9M 2025/26 Highlights RTX - Q3 2025-26 investor presentation 54.8% 9M gross margin, +4.1pp YoY 3 Share buy back increase in share buy back program approved +20 DKKm Revenue 9M revenue growth at constant currency +8% Gross Margin +4.1pp YoY improvement in gross margin 54.8% EBITDA 9M EBITDA 30.1 DKKm +35% This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 4
Q3: 151 DKKm 9M: 416 DKKm For the first nine months of 2025/26, revenue rose by 2% compared to 9M last year reaching DKK 416 million, and by 8.5% when adjusted for currency effects. • Enterprise below last year, impacted by component shortages • Healthcare and ProAudio delivered strong growth • Strong order backlog and customer forecasts for the coming period 101 160 147 140 108 157 151 101 260 407 547 108 264 416 Q1 Q2 Q3 Q4 2024/25 2025/26 2024/25 YTD 2025/26 YTD Revenue 4RTX - Q3 2025-26 investor presentation DKKm This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 5
Q3: 53.3% 9M: 54.8% For the first nine months of 2025/26, gross margin rose by 4.1pp compared to 9M last year, reaching 54.8%. Improvement is driven by: • A more favourable product and customer mix • Higher revenue share from ProAudio and Healthcare • Continued cost discipline in production planning and sourcing 51.7% 53.3% 50.7% 54.8% 50.0% Q3 24/25 Q3 25/26 9M 24/25 9M 25/26 FY 24/25 Gross margin RTX - Q3 2025-26 investor presentation 5 This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 6
Q3: 13.4 DKKm 9M: 30.1 DKKm For the first nine months of 2025/26, EBITDA rose by 7.9 DKKm compared to 9M last year, reaching 30.1 DKKm. Driven by higher gross margin and revenue growth in ProAudio and Healthcare, partly offset by higher capacity costs from strategic hires and organisational development. EBITDA -9 17 15 13 -4 21 13 -9,4 7,2 22,2 35,5 -3.9 16.7 30.1 Q1 Q2 Q3 Q4 2024/25 2025/26 2024/25 YTD 2025/26 YTD EBITDA RTX - Q3 2025-26 investor presentation 6 DKKm This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 7
Enterprise RTX - Q3 2025-26 investor presentation ProAudio Healthcare Revenue EBITDA Q3: 92 DKKm 9M: 258 DKKm Q3: -5.9 DKKm 9M: -15.5 DKKm ▼ -14% YoY (9M) ▼ YoY (9M) Q3 24/25: 106 DKKm 9M 24/25: 299 DKKm Q3 24/25: 11.4 DKKm 9M 24/25: 20.8 DKKm Revenue EBITDA Q3: 30 DKKm 9M: 80 DKKm Q3: 12.2 DKKm 9M: 20.3 DKKm ▲ +42% YoY (9M) ▲ + YoY (9M) Q3 24/25: 18 DKKm 9M 24/25: 56 DKKm Q3 24/25: -6.8 DKKm 9M 24/25: -16.4 DKKm Revenue EBITDA Q3: 30 DKKm 9M: 78 DKKm Q3: 7.1 DKKm 9M: 25.2 DKKm ▲ +51% YoY (9M) ▲ +42% YoY (9M) Q3 24/25: 23 DKKm 9M 24/25: 52 DKKm Q3 24/25: 10.4 DKKm 9M 24/25: 17.8 DKKm 7 This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 8
Outlook 2025/26 Increased 8RTX - Q3 2025-26 investor presentation Revenue: 590 to 625 (from 575 to 625) DKKm EBITDA: 50 to 75 (from 35 to 65) EBIT: 20 to 45 (from 0 to 30) 9M actual vs. outlook Share of full year upper outlook range Share of full year lower outlook range Revenue EBITDA EBIT 9M actual: 415.7 DKKm 67 to 70% of updated full year outlook 9M actual: 30.1 DKKm 40 to 60% of updated full year outlook 9M actual: 8.1 DKKm 18 to 41% of updated full year outlook This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 9
Our Growth Ambition RTX - Q3 2025-26 investor presentation Cultivate new growth markets Healthcare: Accelerate growth from wireless patient monitoring infrastructure Protect and develop core business Retail: Unlock growth with mobility solutions for frontline workers Revenue Ambition Targeting double-digit annual revenue growth towards 2030 Profitability Ambition Targeting EBITDA margin above 15% by 2030 9 This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.
Page 10
Questions? Sign up to receive financial and corporate news RTX - Q3 2025-26 investor presentation 10 This report is for Joel Ivarsson @ Private Investor. Unauthorized redistribution of this report is prohibited.